加拿大衛生部批准Koselugo用於治療第一型神經纖維瘤病成人患者
2026年3月12日
2 min read
規範來源UK
仅摘要30%
核心变化
加拿大衛生部已批准阿斯特捷利康的Koselugo（selumetinib），用於治療患有第一型神經纖維瘤病和叢狀神經纖維瘤的成人患者。
Source Report
AstraZeneca's Koselugo (selumetinib) has been approved in Canada for the treatment of adult patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PNs).
Sigvera Intelligence
Industry Context
健康科技与生物技术
Where this signal fits in the broader landscape.
110 条行业信号Policy Regulatory
Company Activity查看全部
Source Verification
Verified from official source
Publisher—
發佈日期Mar 12, 2026
來源分類Verified Canonical
信号时间线
首次报道Mar 12, 2026
索引时间Mar 12, 2026
发布时间Mar 12, 2026
https://www.astrazeneca.com/media-centre/press-releases/2026/koselugo-approved-in-canada-for-adults-with-neurofibromatosis-type-1.html
Read Full Source置信度:95%
Get cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
登录